Fusion Antibodies present their ‘world class, groundbreaking expertise and services’

In this interview with our CEO, Dr Richard Jones talks about our significant contract announcement with a key US Biotech company, and the organisation’s growth strategy over the next 24 months, focusing on three key pillars:
1.   Commercial excellence
2.   Providing cutting edge services to not only meet, but exceed clients expectations
3.   Sustained investment in R&D to ensure innovation remains at the forefront of the organisation 

Fusion Antibodies